Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125508391 | 12550839 | 1 | I | 20160604 | 20160614 | 20160712 | 20160712 | PER | US-009507513-1606USA006712 | MERCK | 63.73 | YR | F | Y | 117.10000 | KG | 20160712 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125508391 | 12550839 | 1 | PS | PRINIVIL | LISINOPRIL | 1 | Oral | UNK | U | 19558 | TABLET | ||||||||
125508391 | 12550839 | 2 | C | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | 11 MG, ONCE A DAY | U | 0 | 11 | MG | TABLET | QD | |||||
125508391 | 12550839 | 3 | C | XELJANZ | TOFACITINIB CITRATE | 1 | U | 0 | TABLET | ||||||||||
125508391 | 12550839 | 4 | C | METHOTREXATE. | METHOTREXATE | 1 | Oral | 4 TABLETS ONCE A WEEK | U | 0 | 4 | DF | TABLET | /wk |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125508391 | 12550839 | 2 | Rheumatoid arthritis |
125508391 | 12550839 | 3 | Osteoarthritis |
125508391 | 12550839 | 4 | Rheumatoid arthritis |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125508391 | 12550839 | Fluid retention | |
125508391 | 12550839 | Headache | |
125508391 | 12550839 | Joint swelling | |
125508391 | 12550839 | Peripheral swelling |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |